Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? (original) (raw)

Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials

Oncology, 2017

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future

Daniel Neureiter

Cancers, 2021

View PDFchevron_right

Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice

Alessandro Vitale

Cancers, 2019

View PDFchevron_right

New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials

Yitao Mao

International Journal of Biological Sciences

View PDFchevron_right

Predictive Systems Biomarkers of Response to Immune Checkpoint Inhibitors

Peter A J Hilbers

SSRN Electronic Journal

View PDFchevron_right

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

Andrea Wilson

Journal for ImmunoTherapy of Cancer, 2021

View PDFchevron_right

Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

chun jung Chang

Liver Cancer

View PDFchevron_right

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Antonio Giovanni Solimando

View PDFchevron_right

Immune checkpoint inhibitors for unresectable hepatocellular carcinoma

Zeinab Elsayed

Cochrane Database of Systematic Reviews, 2019

View PDFchevron_right

Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Md. Abdul Hye Siddique

Hepatology, 2018

View PDFchevron_right

Immune checkpoint inhibitors for hepatocellular carcinoma

Venkata Nakka

Hepatic Oncology, 2016

View PDFchevron_right

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives

Margaret Ottaviano

Cancers

View PDFchevron_right

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma

Gabriel Prolla

JAMA Network Open, 2021

View PDFchevron_right

Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma

재준 이

View PDFchevron_right

Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma

Giuseppe Toffoli

International Journal of Molecular Sciences

View PDFchevron_right

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges

Ahmed Abudeif

The Oncologist, 2019

View PDFchevron_right

Immune checkpoint inhibitors: recent progress and potential biomarkers

Pramod Darvin

Experimental & Molecular Medicine, 2018

View PDFchevron_right

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment

Antonio Giovanni Solimando

Vaccines

View PDFchevron_right

Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer

Dr margaret Barton Burke

Asia-Pacific Journal of Oncology Nursing

View PDFchevron_right

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors

Silvia Bozzarelli

Cancers

View PDFchevron_right

Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma

George Yeoh

Clinical & translational immunology, 2017

View PDFchevron_right

Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma

Hoang Hai

Scientific Reports, 2020

View PDFchevron_right

Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Li-Yuan Bai

Liver Cancer, 2021

View PDFchevron_right

Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting

Eugenio Caturelli

Journal of Clinical Medicine

View PDFchevron_right

Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation

Amit Mathur

Cancers

View PDFchevron_right

Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma

Jens Kiilgaard

Annals of Oncology, 2019

View PDFchevron_right

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Josephine Tsang

Journal of Clinical Oncology

View PDFchevron_right

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Jean NÈGRE

Frontiers of Medicine, 2019

View PDFchevron_right

Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes

Mercedes Iñarrairaegui

Clinical Cancer Research, 2017

View PDFchevron_right

Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series

Jiahao Wong

Immunotherapy, 2019

View PDFchevron_right

Recent Advances in Immunotherapy for Hepatocellular Carcinoma

Atsushi Takai

Cancers, 2020

View PDFchevron_right

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? (original) (raw)

Related papers